Compare Devon Energy Corp (DVN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Sana Biotechnology Inc — how do they compare? Devon Energy Corp trades at $48.3 (market cap $53.81B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Devon Energy Corp is far larger — about 64.3× Sana Biotechnology Inc's market cap, and Devon Energy Corp pays a 2.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Sana Biotechnology Inc for 23 Days on average.
| DVN | SANA | |
|---|---|---|
Market Cap | $53.81B | $836.71M |
Volume | 11,556,740 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $52.07 | $5.92 |
52-Week Low | $31.74 | $2.68 |
Typical Hold Time | 136 Days | 23 Days |
Enterprise Value | $64.55B | $749.96M |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.69, up 1.69% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 10.63, net income margin of 16.67%, and positive cash flow trends. Recent news highlights activist investor pressure for strategic alternatives, including a potential sale, amid ongoing M&A interest from firms like BP.
The outlook is positive, driven by valuation discounts, earnings beats, and potential asset sales, but risks include oil price volatility and execution challenges. Analyst consensus is strongly bullish with a $62.53 price target, suggesting significant upside from current levels.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
